{
    "info": {
        "nct_id": "NCT04607421",
        "official_title": "AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER",
        "inclusion_criteria": "* Safety Lead-In = Male/female ≥ 18 years old\n* Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally)\n* Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation\n* Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In; none for Phase 3 and Cohort 3. (Note: Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment )\n* Measurable disease (Phase 3 and Cohort 3)/ Measurable or evaluable disease (Safety Lead-in)\n* ECOG PS 0-1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
        "exclusion_criteria": "* Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition\n* Active bacterial or viral infections in 2 weeks prior to starting dosing\n* Symptomatic brain metastases",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Safety Lead-In = Male/female ≥ 18 years old",
            "criterions": [
                {
                    "exact_snippets": "Male/female ≥ 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally)",
            "criterions": [
                {
                    "exact_snippets": "Male/female ≥ 16 years old (where permitted locally)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male/female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed sexes",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "where permitted locally",
                    "criterion": "local regulatory permission for age",
                    "requirements": [
                        {
                            "requirement_type": "local permission",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "colorectal cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage IV CRC",
                    "criterion": "colorectal cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                },
                {
                    "exact_snippets": "contains BRAF V600E mutation",
                    "criterion": "BRAF V600E mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease (Phase 3 and Cohort 3)/ Measurable or evaluable disease (Safety Lead-in)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease (Phase 3 and Cohort 3)",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Measurable or evaluable disease (Safety Lead-in)",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability or evaluability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG PS 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 16 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 16 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition",
            "criterions": [
                {
                    "exact_snippets": "Tumors that are locally confirmed or unknown MSI-H or dMMR",
                    "criterion": "tumor MSI/MMR status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "locally confirmed MSI-H",
                                "unknown MSI-H",
                                "locally confirmed dMMR",
                                "unknown dMMR"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition",
                    "criterion": "eligibility to receive immune checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "pre-existing medical condition",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic brain metastases",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active bacterial or viral infections in 2 weeks prior to starting dosing",
            "criterions": [
                {
                    "exact_snippets": "Active bacterial or viral infections in 2 weeks prior to starting dosing",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Active bacterial or viral infections in 2 weeks prior to starting dosing",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In; none for Phase 3 and Cohort 3. (Note: Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment )",
            "criterions": [
                {
                    "exact_snippets": "Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In",
                    "criterion": "prior systemic treatment regimens in metastatic setting (Safety Lead In)",
                    "requirements": [
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "regimens"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "regimens"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior systemic treatment in metastatic setting: none for Phase 3 and Cohort 3",
                    "criterion": "prior systemic treatment regimens in metastatic setting (Phase 3 and Cohort 3)",
                    "requirements": [
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment",
                    "criterion": "prior adjuvant or neoadjuvant therapy timing relative to relapse/metastasis",
                    "requirements": [
                        {
                            "requirement_type": "relapse/metastasis interval from end of adjuvant/neoadjuvant therapy",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}